Randomized Trial of Vaccines for Zaire Ebola Virus Disease

Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries

(2021) Moses Badio et al.   Trials

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial

(2021) Muhammed O Afolabi et al.   LANCET INFECTIOUS DISEASES

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial

(2021) David Ishola et al.   LANCET INFECTIOUS DISEASES

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa

(2021) Houreratou Barry et al.   PLOS MEDICINE

Safety, immunogenicity and risk–benefit analysis of rVSV-ΔG-ZEBOV-GP (V920) Ebola vaccine in Phase I–III clinical trials across regions

(2020) Bache Emmanuel Bache et al.   Future Microbiology

Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate

(2020) Ramon Roozendaal et al.   npj Vaccines

Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial

(2020) Andrew J Pollard et al.   LANCET INFECTIOUS DISEASES

Randomized clinical trial examining safety and immunogenicity of heterologous prime-boost Ebola vaccines, Ad26.ZEBOV and MVA-BN-Filo: 12-month data from Uganda and Tanzania

(2019) Zacchaeus Anywaine et al.   JOURNAL OF INFECTIOUS DISEASES

Randomized clinical trial examining safety and immunogenicity of heterologous prime-boost Ebola vaccines, Ad26.ZEBOV and MVA-BN-Filo: 12-month data from Nairobi, Kenya

(2019) Gaudensia Mutua et al.   JOURNAL OF INFECTIOUS DISEASES

Prevention of Ebola virus disease through vaccination: where we are in 2018

(2018) Yves Lévy et al.   LANCET

Aging-related changes in human T-cell repertoire over 20 years delineated by deep sequencing of peripheral T-cell receptors

(2017) Kengo Yoshida et al.   EXPERIMENTAL GERONTOLOGY

Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)

(2017) Ana Maria Henao-Restrepo et al.   LANCET

Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report

(2017) Pierre-Stéphane Gsell et al.   LANCET INFECTIOUS DISEASES

Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study

(2017) D Gray Heppner et al.   LANCET INFECTIOUS DISEASES

Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia

(2017) Stephen B. Kennedy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial

(2017) Selidji T. Agnandji et al.   PLOS MEDICINE

The cost of an Ebola case

(2015) Sarah M. Bartsch et al.   Pathogens and Global Health